HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test powerful new drug cocktail to fight Fast-Growing lymphomas
Disease control Recruiting nowThis early-stage study is testing the safety of adding one or two new targeted drugs to a standard chemotherapy regimen for people with untreated, fast-growing B-cell lymphomas. The goal is to see if this combination is tolerable for patients and to gather initial data on its eff…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for Tough-to-Treat lymphomas: trial tests powerful drug combo
Disease control Recruiting nowThis study is testing whether adding a new immunotherapy drug called epcoritamab to a standard chemotherapy regimen (EPOCH-R) is safe and more effective for treating aggressive B-cell lymphomas. The trial will enroll about 18 adults who have not yet received treatment for their s…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Targeted drug combo offers hope for Tough-to-Treat leukemia
Disease control Recruiting nowThis study is testing a combination of a targeted cancer drug (inotuzumab ozogamicin), low-intensity chemotherapy, and an immunotherapy drug (blinatumomab) for adults with acute lymphoblastic leukemia (ALL). It focuses on older patients (60+) or younger patients who are too frail…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New 'Living Drug' trial offers hope for lymphoma patients out of options
Disease control Recruiting nowThis is a first-in-human study testing the safety and early effectiveness of a new cell therapy called SynKIR-310. It is for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments, including other CAR-T therapies. The main goa…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC